Reviewer's report

Title: Controversies in Neurology: why monoamine oxidase B inhibitors could be the best choice for initial treatment of Parkinson's Disease

Version: 1 Date: 6 June 2011

Reviewer: Lawrence Elmer

Reviewer's report:

Major Compulsory Revisions
The authors have rendered strong arguments and adequate references for their position paper. However, they have not included any discussion of dietary (tyramine) and serotonin considerations complicating the decision of whether or not to use MAO-B inhibitors. This remains a point of considerable concern for some neurologists and many other physicians. There have been appropriate, placebo-controlled studies addressing these issues and this needs to be incorporated before final determination can be made whether this manuscript should be published or not.
Goren, T., J Clinical Pharmacology, 50:1420-1428

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I serve on the speaker's bureau for Novartis, Teva Neuroscience, and GSK. I have received grants from Teva and GSK and I serve on the scientific advisory board of Teva.